ESR1 and breast cancer: AGR2 and AGR3 expression are coupled in EsR positive breast cancer and the combination of AGR2 and AGR3 as biomarkers resulted in increased sensitivity and specificity thus suggesting that they can be used as a prognostic factor [113].